Vaccinex (NASDAQ:VCNX) released its quarterly earnings results on Tuesday. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.66) by $0.10, Fidelity Earnings reports. The business had revenue of $0.40 million during the quarter. Vaccinex had a negative return on equity of 528.50% and a negative net margin of 4,688.97%.
Shares of NASDAQ:VCNX traded up $0.25 during mid-day trading on Friday, reaching $5.00. 394 shares of the company traded hands, compared to its average volume of 2,546. The company’s 50 day moving average price is $5.98 and its 200-day moving average price is $5.76. The firm has a market cap of $80.26 million, a PE ratio of -0.92 and a beta of 1.64. Vaccinex has a 52 week low of $3.32 and a 52 week high of $8.49.
A number of equities research analysts have issued reports on VCNX shares. ValuEngine downgraded Vaccinex from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Zacks Investment Research restated a “hold” rating on shares of Vaccinex in a research note on Saturday, October 19th.
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
Further Reading: Guidelines for Successful Channel Trading
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.